natgillin/translations-raw huggingface dataset:
For women aged 50 to 79 who are taking oestrogenprogestagen HRT over 5 years, there will be 13 to 20 cases in 1000 users (i.e. an extra 4 to 6 cases). 
Pri ženskah med 50. in 79. letom starosti, ki uporabljajo estrogensko-progestogensko HNZ v obdobju petih let, bo takih primerov od 13 do 20 na 1.000 žensk (torej od 4 do 6 dodatnih primerov).
The WHI trial found no increase in risk of breast cancer in hysterectomised women using oestrogen-only HRT. 
V okviru preskušanja WHI (Women's Health Initiative) niso ugotovili povečanega tveganja za raka dojke pri histerektomiranih ženskah, ki so uporabljale samo estrogensko HNZ.
Take special care with [invented name] 
Bodite posebno pozorni pri uporabi zdravila [izmišljeno ime]
- Gallbladder disease 
- bolezen žolčnika.
Long-term use of oestrogen-only and combined oestrogen-progestogen HRT has been associated with a slightly increased risk of ovarian cancer. 
Dolgotrajna uporaba samo estrogenskega ali estrogensko-progestogenskega HNZ je bila povezana z rahlo povečanim tveganjem za raka jajčnikov.
Vaginitis including infection of the genitals caused by a fungus, changes in sexual drive, mood disturbances, dizziness, headache, migraine, anxiety, intolerance to contact lenses, blood clots in a vein (thrombosis), nausea, bloating, abdominal pain, hirsutism, pruritus, rash, oedema 
Vaginitis, vključno z okužbo spolovil, ki jo povzročajo glive, spremembe spolne sle, motnje razpoloženja, omotica, glavobol, migrena, tesnoba, neprenašanje kontaktnih leč, krvni strdki v veni (tromboza), slabost, napihnjenost, bolečina v trebuhu, prekomerna poraščenost, srbenje, izpuščaj, otekline
* No differentiation was made between ischaemic and haemorrhagic stroke 
* Razlikovanja med ishemično in hemoragično možgansko kapjo ni bilo.
If you use too much [invented name] on one occasion, side effects such as nausea may occur. 
Če ste uporabili večji odmerek zdravila [izmišljeno ime], kot bi smeli Če ste enkrat uporabili prevelik odmerek zdravila [izmišljeno ime], se lahko pojavijo neželeni učinki, kot je na primer slabost.
In rare cases benign, and in even rarer cases malignant liver tumours leading to isolated cases to life-threatening intra-abdominal haemorrhage have been observed after the use of hormonal substances such as those contained in [invented name]. 
V redkih primerih so po uporabi hormonskih snovi, kot so tiste, ki jih vsebuje zdravilo [izmišljeno ime], opazili benigne, še redkeje pa tudi maligne tumorje jeter, ki so v posameznih primerih povzročili smrtno nevarne intraabdominalne krvavitve.
- history of malignant oestrogen-dependent tumours - tumours of the womb (leiomyoma, uterine myoma). 
- od estrogena odvisnih malignih tumorjev v anamnezi; - tumorjev maternice (leiomioma, mioma maternice).
Evidence suggests that taking combined oestrogen-progestagen and possibly also oestrogenonly HRT increases the risk of breast cancer. 
Rak dojke Dokazi kažejo, da uporaba kombiniranega estrogensko-progestogenskega in morebiti tudi samo estrogenskega HNZ poveča tveganje za raka dojke.
[The text below should be inserted in this section. 
[Besedilo v nadaljevanju je treba vstaviti v to poglavje.
Incidence per 1000 women placebo arm over 5 year period* 
Incidenca na 1.000 žensk, ki so prejemale placebo, v obdobju petih let*
You must always follow the directions for use; if not, [invented name] may not work properly. 
Navodila za uporabo morate vedno upoštevati, sicer se lahko zgodi,
Chloasma/melasma, hirsutism, pruritus, rash 
Bolezni kože in podkožja alopecija kloazma/melazma, hirzutizem,
Before you use [invented name] 
Preden boste uporabili zdravilo [izmišljeno ime]
less than 1 in 10,000 patients treated 
manj kot 1 bolnica od 10.000, ki uporabljajo zdravilo
For women in their 50s who are taking HRT, there will be 11 cases in 1000 users, over 5 years (i.e. 3 extra cases). 
Pri ženskah pri 50 letih, ki uporabljajo HNZ, bo v petih letih takih primerov 11 na 1.000 žensk (torej 3 dodatni primeri).
Annex III Amendments to relevant sections of the summary of product characteristics and package leaflets 
Dopolnitve zadevnih poglavij povzetka glavnih značilnosti zdravila in navodil za uporabo
If you forget to use [invented name] 
Če ste pozabili uporabiti zdravilo [izmišljeno ime]:
The relationship between pre-existing hypertriglyceridaemia and low dose local vaginal oestrogen therapy is unknown. 
Povezava med že obstoječo hipertrigliceridemijo in nizkoodmernim lokalnim vaginalnim estrogenskim zdravljenjem ni znana.
Musculoskeletal, connective tissue and bone disorders 
Bolezni mišično skeletnega sistema, vezivnega tkiva in kosti artralgija, krči v nogah
[The text below should be inserted by replacing the existing text in the relevant paragraph] 
[Besedilo v nadaljevanju je treba vstaviti namesto obstoječega besedila v ustreznem odstavku.]
The maximum duration of treatment is 4 weeks. 
Zdravljenje lahko traja največ štiri tedne.
How to use [invented name] 
KAKO UPORABLJATI ZDRAVILO [izmišljeno ime]
HOW TO USE [invented name] 
Kako uporabljati zdravilo [izmišljeno ime]
For the treatment of atrophic disorders of the vagina and vulva, which are due to a lack of oestrogen, e.g. atrophic vaginitis, coital problems, vaginal stenosis (narrowing), vulvar atrophy with burning and itching 
za zdravljenje atrofičnih sprememb nožnice in vulve, ki so posledica pomanjkanja estrogena, na primer pri atrofičnem vaginitisu, težavah pri spolnih odnosih, stenozi (zožitvi) nožnice ali atrofiji vulve, ki jo spremljata pekoč občutek in srbenje.
[All current text in this section should be deleted and replaced by the text below] 
[Celotno obstoječe besedilo v tem poglavju je treba izbrisati in ga nadomestiti s spodnjim besedilom.]
[This section should have all of the following text only] 
[To poglavje mora vsebovati samo celotno besedilo, ki je navedeno v nadaljevanju.]
1 to 10 patients treated out of 100 
1 do 10 bolnic od 100, ki uporabljajo zdravilo
[invented name] should not be used immediately prior to sexual intercourse or as a lubricant. 
Zdravilo [izmišljeno ime] se ne sme uporabljati tik pred spolnim odnosom ali namesto lubrikanta.
Therefore, prolonged treatment beyond 4 weeks is not recommended. 
zdravljenje, daljše od štirih tednov, ni priporočljivo.
− when using [invented name] at the same time as latex products (e.g. condoms, diaphragms). 
− Kadar zdravilo [izmišljeno ime] uporabljate sočasno z izdelki iz lateksa (kot so npr.
Women aged 50 to 69 who are not taking HRT, on average about 2 women in 1000 will be diagnosed with ovarian cancer over a 5-year period. 
Pri ženskah med 50. in 69. letom starosti, ki ne uporabljajo HNZ, bodo v petih letih raka jajčnikov v povprečju odkrili pri približno 2 od 1.000 žensk.
Incidence per 1000 women placebo arm over 5 years 
Incidenca na 1.000 žensk, ki so prejemale placebo, v petih letih
[The wording of the indication should be deleted and the text below should be inserted in its place] 
[Besedilo indikacije je treba izbrisati in ga nadomestiti z besedilom, ki je navedeno spodaj.]
For women who have been taking HRT for 5 years, there will be between 2 and 3 cases per 1000 users (i.e. up to 1 extra case). 
Pri ženskah, ki so pet let uporabljale HNZ, bodo odkrili od 2 do 3 primere na 1.000 žensk (torej največ 1 dodaten primer).
[The text below should be deleted] 
[Besedilo v nadaljevanju je treba izbrisati.]
- An up to 2-fold increased risk of having breast cancer diagnosed is reported in women taking combined oestrogen-progestogen therapy for more than 5 years. 
- Pri ženskah, ki uporabljajo kombinirano estrogensko-progestogensko zdravljenje več kot pet let, poročajo o do dvakrat večjem tveganju za diagnosticiranje raka dojke.
Oestrogens increase thyroid binding globulin (TBG), leading to increased circulating total thyroid hormone (as measured by protein-bound iodine (PBI)), T4 levels (by column or by radio-immunoassay) or T3 levels (by radio-immunoassay). 
(merjenih z beljakovinsko vezanim jodom (PBI - protein-bound iodine)), koncentracije T4 (s kolono ali radioimunskim testom) ali koncentracije T3 (z radioimunskim testom).
The following adverse reactions have been associated with oral and/or transdermal oestrogen therapy (class effects): 
Neželeni učinki, navedeni v nadaljevanju, so bili povezani s peroralnim in/ali transdermalnim zdravljenjem z estrogenom (neželeni učinki, značilni za skupino zdravil):
In particular, if you experience unexpected genital bleeding you must discontinue treatment with [invented name] and consult a doctor 
Če se pojavi nepričakovana krvavitev, je treba zdravljenje z zdravilom [izmišljeno ime]
Section 4.3 Contraindications [The text below should be inserted by replacing the existing text of this section] 
Poglavje 4.3 Kontraindikacije [Besedilo v nadaljevanju je treba vstaviti namesto obstoječega besedila v tem poglavju.]
[Invented name] is for use in postmenopausal women only. 
Nosečnost in dojenje Zdravilo [izmišljeno ime] je namenjeno samo za uporabo pri ženskah po menopavzi.
However, the metabolism of oestrogens may be increased by concomitant use of substances known to induce drug-metabolising enzymes, specifically cytochrome P450 enzymes, such as anticonvulsants (e.g. phenobarbital, phenytoin, carbamazepine) and anti-infectives (e.g. rifampicin, rifabutin, nevirapine, efavirenz). 
fenobarbital, fenitoin, karbamazepin) in protimikrobna zdravila (npr. rifampicin, rifabutin, nevirapin, efavirenz).
There is no evidence from randomised controlled trials of protection against myocardial infarction in women with or without existing CAD who received combined oestrogenprogestagen or oestrogen-only. 
Randomizirana kontrolirana preskušanja pri ženskah z obstoječo BKA ali brez nje, ki so prejemale kombinirano estrogensko-progestogensko ali samo estrogensko HNZ, niso pokazala zaščite pred srčnim infarktom.
1 to 10 patients treated out of 1,000 
1 do 10 bolnic od 1.000, ki uporabljajo zdravilo
Uncommon > 1/1000 to <1/100 (> 0.1% and 
> 1/1.000 do <1/100 (> 0,1 % in < 1
Women aged 50 to 79 who are not taking HRT, on average, 9 to 14 in 1000 will be diagnosed with breast cancer over a 5-year period. 
Primerjava Pri ženskah med 50. in 79. letom starosti, ki ne uporabljajo HNZ, bodo v petih letih v povprečju odkrili raka dojke pri 9 do 14 na 1.000 žensk.
[invented name] is a cream for vaginal use. 
Kako uporabljati zdravilo [izmišljeno ime] Zdravilo [izmišljeno ime] je krema za vaginalno uporabo.
[The text below should be inserted in this section and the existing text should be deleted] 
[Besedilo v nadaljevanju je treba vstaviti v to poglavje, obstoječe besedilo pa izbrisati.]
Common ≥ 1/100 to < 1/10 (≥ 1% and 
Organski sistem Pogosti ≥ 1/100 do < 1/10 (≥ 1 % in
Oedema 
Prednizolon
[The text below should be inserted in this section.] 
[Besedilo v nadaljevanju je treba vstaviti v to poglavje.]
[invented name] should not be used in the following cases: - Known, past or suspected breast cancer - Known or suspected oestrogen-dependent malignant tumours (e.g. endometrial cancer) - Undiagnosed genital bleeding - Untreated endometrial hyperplasia - Previous or current venous thromboembolism (deep venous thrombosis, pulmonary embolism) - Known thrombophilic disorders (e.g. protein C, protein S, or antithrombin deficiency, 
Zdravilo [izmišljeno ime] se ne sme uporabljati v primeru: - znanega raka dojke, raka dojke v anamnezi ali ob sumu nanj; - znanih od estrogena odvisnih malignih tumorjev (kot je na primer rak endometrija) ali ob sumu nanje; - nediagnosticirane genitalne krvavitve; - nezdravljene hiperplazije endometrija;
Maturation of the vaginal epithelium is dependent upon oestrogens. 
Od estrogenov je odvisno dozorevanje epitelija nožnice.
The number of extra cases of stroke due to use of HRT will increase with age. 
Število dodatnih primerov možganske kapi zaradi uporabe HNZ
Reproductive system and breast disorders 
Motnje reprodukcije in dojk krvavkast izcedek
Section 4.2 Posology and method of administration [The text below should be inserted by replacing the existing text of this section] 
Poglavje 4.2 Odmerjanje in način uporabe [Besedilo v nadaljevanju je treba vstaviti namesto obstoječega besedila v tem poglavju.]
[The currently existing text should be deleted from this section and be replaced by the text below.] 
[Obstoječe besedilo je treba izbrisati iz tega poglavja in ga nadomestiti z besedilom v nadaljevanju.]
[The text below should be inserted in this section and any existed text should be deleted] 
[Besedilo v nadaljevanju je treba vstaviti v to poglavje, morebitno obstoječe besedilo pa izbrisati.]
It is caused by a drop in the levels of oestrogen in your body. 
Medicinski izraz za to je „atrofija nožnice“, ki nastane zaradi znižanja ravni estrogena v telesu.
frequency cannot be estimated from the available data Uncommon: temporarily mild local irritation (e.g. itching, burning) and slight discharge may occur. 
Občasni: prehodno se lahko pojavita blago lokalno draženje (na primer srbenje, pekoč občutek) in rahel izcedek.
Combined oestrogen-progestogen 
HNZ s samim estrogenom kombinirani estrogen-progestogen
Million Women Study - Estimated additional risk of breast cancer after 5 years' use Age range (years) Additional cases per 1000 users of HRT over 5 year period* 
Študija Million Women Study - ocenjeno dodatno tveganje za raka dojke po petletni uporabi Razpon starosti (leta)
During treatment with [invented name], after each application there is a transient increase in plasma estradiol levels above the physiological range of postmenopausal women. 
Med zdravljenjem z zdravilom [izmišljeno ime] koncentracija estradiola v plazmi po vsaki uporabi zdravila prehodno preseže fiziološke koncentracije, ki so običajne pri ženskah po menopavzi.
1 to 10 patients treated out of 10,000 
1 do 10 bolnic od 10.000, ki uporabljajo zdravilo
[This section should have all of the following text] 
[To poglavje mora vsebovati celotno besedilo, ki je navedeno v nadaljevanju.]
- known or suspected benign or malignant oestrogen-dependent tumours e.g. uterine leiomyoma, endometrial cancer) - history of malignant oestrogen-dependent tumours - Unspecified genital bleeding - Untreated endometrial hyperplasia - Skin diseases in the external genital area caused by bacterial, fungal, or viral infections 
- znane preobčutljivosti za estradiol, prednizolon, cetil in stearilalkohol ali katero koli pomožno snov zdravila [izmišljeno ime]; - znanih od estrogena odvisnih benignih ali malignih tumorjev (na primer leiomiom maternice, rak endometrija) ali ob sumu nanje; - od estrogena odvisnih malignih tumorjev v anamnezi; - neopredeljenih genitalnih krvavitev; - nezdravljene hiperplazije endometrija;
- Migraine or (severe) headache 
- visok krvni tlak; - migrene ali hudi glavoboli;
In addition, due to the content of the corticosteroid prednisolone in [invented name] , skin atrophy might occur with prolonged use, further increasing systemic exposure to oestradiol. 
[izmišljeno ime] pri daljši uporabi pojavi atrofija kože, ki še poveča sistemsko izpostavljenost estradiolu.
Ischaemic stroke 
Rahel izcedek
Undesirable effects - such as gastrointestinal complaints, nausea, etc - may occur after accidental or intentional administration of large amounts of [invented name]. 
Po nenamerni ali namerni uporabi velikih odmerkov zdravila [izmišljeno ime] se lahko pojavijo neželeni učinki, kot so težave s prebavili, navzea itd. Zdravljenje je simptomatsko.
Changes in weight (increase or decrease), increased triglycerides 
(povečanje ali zmanjšanje),
During treatment with [invented name], after each application there is an increase in plasma oestradiol levels above the physiological range of postmenopausal women. 
Med zdravljenjem z zdravilom [izmišljeno ime] koncentracija estradiola v plazmi po vsaki uporabi zdravila preseže fiziološke koncentracije, ki so običajne pri ženskah po menopavzi.
Looking at women in their 50s who are not taking HRT, on average, over a 5-year period, 4 to 7 in 1000 would be expected to get a blood clot in a vein. 
Pri ženskah pri 50 letih, ki ne uporabljajo HNZ, bi se po pričakovanjih krvni strdek v veni v petih letih pojavil pri 4 do 7 na 1.000 žensk.
[The text below should be all deleted from this section] 
[Besedilo v nadaljevanju je treba v celoti izbrisati iz tega poglavja.]
- Otosclerosis 
- porfirije.
[invented name] is not indicated during pregnancy. 
Zdravilo [izmišljeno ime] ni indicirano med nosečnostjo.
Looking at women in their 50s who are not taking HRT, on average, 8 in 1000 would be expected to have a stroke over a 5-year period. 
Pri ženskah pri 50 letih, ki ne uporabljajo HNZ, bi se po pričakovanjih možganska kap v petih letih pojavila pri 8 od 1.000 žensk.
In women with an intact uterus the risk of endometrial hyperplasia and carcinoma is increased when oestrogens are administered alone for prolonged periods. 
Med dolgotrajno uporabo samih estrogenov se pri ženskah z ohranjeno maternico poveča tveganje za hiperplazijo in karcinom endometrija.
Driving and using machines 
Navodilo za uporabo
Do not use up any remaining content after completing treatment course. 
Po končanem zdravljenju ne smete porabiti kreme, ki vam je morda ostala.
A relationship between ovarian cancer risk and local vaginal oestrogen therapy is uncertain. 
Povezava med tveganjem za raka jajčnikov in lokalnim vaginalnim estrogenskim zdravljenjem je negotova.
- Risk factors for thromboembolic disorders (see below) 
- leiomiomi (fibroidi v materničnem tkivu) ali endometrioza; - dejavniki tveganja za trombembolične motnje (glejte spodaj);
A relationship between breast cancer risk and local vaginal oestrogen therapy is uncertain. 
Povezava med tveganjem za raka dojke in lokalnim vaginalnim estrogenskim zdravljenjem je negotova.
Gastrointestinal disorders 
zvišani trigliceridi
The following adverse events have also been associated with oral and/or transdermal oestrogen therapy: 
S peroralnim in/ali transdermalnim zdravljenjem z estrogenom so bili povezani tudi naslednji neželeni dogodki:
Risk estimates have been drawn from systemic exposure and it is not known how these apply to local treatments: 
Ocene tveganja so bile podane na podlagi sistemske izpostavljenosti, zato ni znano,
WHI studies combined - Additional risk of ischaemic stroke* over 5 years' use 
Študije WHI skupaj - dodatno tveganje za ishemično možgansko kap* med petletno uporabo Razpon starosti (leta)
Do not use [invented name] if - You are allergic (hypersensitive) to estradiol or any of the other ingredients of [invented name] (listed in Section 6 Further information) - You have or have ever had breast cancer, or you are suspected of having it - You have or have ever had cancer which is sensitive to oestrogens, such as cancer of the womb lining (endometrium), or you are suspected of having it - You have any unexplained vaginal bleeding - You have excessive thickening of the womb lining (endometrial hyperplasia) that is not being treated - You have or have ever had a blood clot in a vein (thrombosis), such as in the legs (deep venous thrombosis) or the lungs (pulmonary embolism) - You have a blood clotting disorder (such as protein C, protein S, or antithrombin deficiency) - You have or have recently had a disease caused by blood clots in the arteries, such as a heart attack, stroke or angina - You have or have ever had a liver disease and your liver function tests have not returned to normal - You have a rare blood problem called “porphyria”, which is passed down in families (inherited). 
- imate ali ste pred kratkim imeli bolezen, ki jo povzročajo krvni strdki v arterijah, na primer srčno kap, možgansko kap ali angino pektoris; - če imate ali ste kdaj imeli bolezen jeter in izvidi preiskav delovanja jeter še niso normalni; - če imate redko krvno motnjo, imenovano „porfirija“, ki se prenaša znotraj družine (dedna motnja).
Additional cases per 1000 users over 5 years 
Dodatno število primerov na 1.000 žensk, ki so uporabljale HNZ, v petih letih
A relationship between ischaemic stroke and low dose local vaginal oestrogen therapy is uncertain. 
Povezava med tveganjem za ishemično možgansko kap in nizkoodmernim lokalnim vaginalnim estrogenskim zdravljenjem je negotova.
Given that systemic exposure occurs during treatment with [Invented name], prolonged treatment beyond 4 week is not recommended. 
Ker med zdravljenjem z zdravilom [izmišljeno ime] pride do sistemske izpostavljenosti,
[The text below should be deleted from this section] 
[Besedilo v nadaljevanju je treba izbrisati iz tega poglavja.]
Other adverse reactions have been reported in association with oestrogen/progestogen treatment. 
V povezavi z estrogensko-progestogenskim zdravljenjem so poročali tudi o drugih neželenih učinkih.
A relationship between venous thromboembolism and local vaginal oestrogen therapy is uncertain. 
Povezava med tveganjem za vensko trombembolijo in lokalnim vaginalnim estrogenskim zdravljenjem je negotova.
For women in their 50s who have been taking oestrogen-progestagen HRT for over 5 years, there will be 9 to 12 cases in 1000 users (i.e. 5 extra cases) For women in their 50s who have had their womb removed and have been taking oestrogenonly HRT for over 5 years, there will be 5 to 8 cases in 1000 users (i.e. 1 extra case). 
Pri ženskah pri 50 letih, ki uporabljajo estrogensko-progestogensko HNZ več kot pet let, bo takih primerov od 9 do 12 na 1.000 žensk (torej pet dodatnih primerov).
If you notice any of the following when using HRT: - Migraine-like headaches which happen for the first time - Yellowing of your skin or the whites of your eyes (jaundice). 
če zanosite; če opazite znake krvnega strdka, kot so: - boleče otekanje in rdečina nog; - nenadna bolečina v prsnem košu;
Nausea, bloating, abdominal pain 
Bolezni prebavil navzeja, napihnjenost, bolečina v trebuhu
Abnormal uterine bleeding (breakthrough bleeding/spotting), breast pain, breast tenderness, breast enlargement, breast discharge, leukorrhoea 
bolečine v dojkah, občutljivost dojk, povečanje dojk, izcedek iz dojk, levkoreja
- Leiomyoma (uterine fibroids) or endometriosis 
- rak dojke; - hiperplazija in karcinom endometrija;
Skin and subcutaneous tissue disorders 
Bolezni jeter, žolčnika in žolčevodov bolezen žolčnika
- Gall bladder disease - Various skin disorders: o discoloration of the skin especially of the face or neck known as “pregnancy patches (chloasma) o painful reddish skin nodules (erythema nodosum) o rash with target-shaped reddening or sores (erythema multiforme) 
o boleči rdečkasti kožni vozliči (nodozni eritem), o izpuščaj z rdečino ali razjedami v obliki tarče (multiformni eritem).
Nervous system disorders 
Ishemična možganska kap
- Asthma - Epilepsy - Diabetes - Gallstones - High blood pressure - Migraines or severe headaches - A liver disorder, such as a benign liver tumour 
Zdravljenje je treba prekiniti, če se odkrije kontraindikacija ali če se pojavi karkoli od naslednjega: - zlatenica ali poslabšanje delovanja jeter; - znatno zvišanje krvnega tlaka; - novonastali glavobol migrenskega tipa;
- Growth of womb lining outside your womb (endometriosis) or a history of excessive growth of the womb lining (endometrial hyperplasia) - A disease affecting the eardrum and hearing (otosclerosis) - A disease of the immune system that affects many organs of the body (systemic lupus erythematosus, SLE) - Increased risk of getting an oestrogen-sensitive cancer (such as having a mother, 
- dejavniki tveganja za od estrogena odvisne tumorje, kot so na primer dedne predispozicije za raka dojke v 1. kolenu; - hipertenzija; - bolezni jeter (npr. adenom jeter); - sladkorna bolezen s prizadetostjo ožilja ali brez nje; - holelitiaza; - migrena ali (hud) glavobol; - sistemski eritematozni lupus; - hiperplazija endometrija v anamnezi (glejte spodaj); - epilepsija; - astma; - otoskleroza.
Do not use [invented name] immediately before sexual intercourse or as a lubricant, to prevent possible side effects in your partner. 
Ne uporabljajte zdravila [izmišljeno ime] tik pred spolnim odnosom ali namesto lubrikanta,
Risk of ischaemic stroke 
Tveganje za ishemično možgansko kap
05 March 2014 
5. marec 2014
The European Commission issued a decision on 05 March 2014. 
Evropska komisija je sklep izdala dne 5. marca 2014.